

## **Product datasheet for TF316980**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **MAPRE1 Human shRNA Plasmid Kit (Locus ID 22919)**

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** MAPRE1 Human shRNA Plasmid Kit (Locus ID 22919)

Locus ID: 22919 Synonyms: EB1

**Vector:** pRFP-C-RS (TR30014)

E. coli Selection: Chloramphenicol (34 ug/ml)

Mammalian Cell

Selection:

Puromycin

Format: Retroviral plasmids

Components: MAPRE1 - Human, 4 unique 29mer shRNA constructs in retroviral RFP vector(Gene ID =

22919). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRFP-C-RS Vector, TR30015, included for free.

**RefSeq:** NM 012325, NM 012325.1, NM 012325.2, BC106068, BC106068.1, BC040410, BC109281,

BC128442, BM983860, NM 012325.3

UniProt ID: Q15691

Summary: The protein encoded by this gene was first identified by its binding to the APC protein which

is often mutated in familial and sporadic forms of colorectal cancer. This protein localizes to microtubules, especially the growing ends, in interphase cells. During mitosis, the protein is associated with the centrosomes and spindle microtubules. The protein also associates with components of the dynactin complex and the intermediate chain of cytoplasmic dynein. Because of these associations, it is thought that this protein is involved in the regulation of microtubule structures and chromosome stability. This gene is a member of the RP/EB

family. [provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).